MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE^® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.¹

Originally published via Source Article.

MONTRÉAL, 01 sept. 2026 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (« Knight ») (TSX : GUD), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui avoir reçu l’approbation réglementaire de l’INVIMA, l’organisme de réglementation sanitaire de la Colombie, pour TAVALISSE^® (fostamatinib disodique hexahydraté) pour le traitement des patients adultes atteints de thrombocytopénie immunitaire chronique (TPI) ayant présenté une réponse insuffisante, une perte de réponse ou une intolérance à un traitement antérieur par corticostéroïdes et immunoglobulines intraveineuses¹.

Originally published via Source Article.

MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE^® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.¹

Originally published via Source Article.

MONTRÉAL, 01 sept. 2026 (GLOBE NEWSWIRE) — Thérapeutique Knight inc. (« Knight ») (TSX : GUD), société pharmaceutique panaméricaine (hors États-Unis), a annoncé aujourd’hui avoir reçu l’approbation réglementaire de l’INVIMA, l’organisme de réglementation sanitaire de la Colombie, pour TAVALISSE^® (fostamatinib disodique hexahydraté) pour le traitement des patients adultes atteints de thrombocytopénie immunitaire chronique (TPI) ayant présenté une réponse insuffisante, une perte de réponse ou une intolérance à un traitement antérieur par corticostéroïdes et immunoglobulines intraveineuses¹.

Originally published via Source Article.

MONTREAL, Sept. 01, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today that it has received regulatory approval from INVIMA, the Colombian health regulatory agency, for TAVALISSE^® (fostamatinib disodium hexahydrate) for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response, loss of response, or intolerance to prior treatment with corticosteroids and intravenous immunoglobulin.¹

Originally published via Source Article.

GUELPH, Ontario, Sept. 01, 2026 (GLOBE NEWSWIRE) — (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-nine cents ($0.29) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-nine cents ($0.29) per Class B Common Share of HPS, representing an increase of $0.015 or 5.5%. The dividend will be payable on September 24, 2026 to shareholders of record at the close of business on September 17, 2026. The ex-dividend date is September 17, 2026.

Originally published via Source Article.

GUELPH, Ontario, Sept. 01, 2026 (GLOBE NEWSWIRE) — (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-nine cents ($0.29) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-nine cents ($0.29) per Class B Common Share of HPS, representing an increase of $0.015 or 5.5%. The dividend will be payable on September 24, 2026 to shareholders of record at the close of business on September 17, 2026. The ex-dividend date is September 17, 2026.

Originally published via Source Article.

GUELPH, Ontario, Sept. 01, 2026 (GLOBE NEWSWIRE) — (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-nine cents ($0.29) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-nine cents ($0.29) per Class B Common Share of HPS, representing an increase of $0.015 or 5.5%. The dividend will be payable on September 24, 2026 to shareholders of record at the close of business on September 17, 2026. The ex-dividend date is September 17, 2026.

Originally published via Source Article.

GUELPH, Ontario, Sept. 01, 2026 (GLOBE NEWSWIRE) — (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-nine cents ($0.29) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-nine cents ($0.29) per Class B Common Share of HPS, representing an increase of $0.015 or 5.5%. The dividend will be payable on September 24, 2026 to shareholders of record at the close of business on September 17, 2026. The ex-dividend date is September 17, 2026.

Originally published via Source Article.

GUELPH, Ontario, Sept. 01, 2026 (GLOBE NEWSWIRE) — (TSX: HPS.A) The Board of Directors of Hammond Power Solutions Inc. (“HPS”) declared a quarterly cash dividend of twenty-nine cents ($0.29) per Class A Subordinate Voting Share of HPS and a quarterly cash dividend of twenty-nine cents ($0.29) per Class B Common Share of HPS, representing an increase of $0.015 or 5.5%. The dividend will be payable on September 24, 2026 to shareholders of record at the close of business on September 17, 2026. The ex-dividend date is September 17, 2026.

Originally published via Source Article.